scholarly journals Clinical usefulness of serum levels of soluble fms-like tyrosine kinase 1/placental growth factor ratio to rule out preeclampsia in women with new-onset lupus nephritis during pregnancy

2018 ◽  
Vol 8 (2) ◽  
pp. 95-100 ◽  
Author(s):  
Chikako Hirashima ◽  
Manabu Ogoyama ◽  
Miyuki Abe ◽  
Satoru Shiraishi ◽  
Taro Sugase ◽  
...  
Keyword(s):  
Growth Factor ◽  
Lupus Nephritis ◽  
Tyrosine Kinase ◽  
Serum Levels ◽  
Placental Growth Factor ◽  
Clinical Usefulness ◽  
Factor Ratio ◽  
Rule Out ◽  
New Onset

scholarly journals Maternal Serum Placental Growth Factor, Soluble Fms-Like Tyrosine Kinase-1, and Soluble Endoglin in Twin Gestations and the Risk of Preeclampsia—A Systematic Review

2020 ◽  
Vol 9 (1) ◽  
pp. 183 ◽  
Author(s):  
Katarzyna Kosinska-Kaczynska ◽  
Magdalena Zgliczynska ◽  
Szymon Kozlowski ◽  
Lukasz Wicherek
Keyword(s):  
Growth Factor ◽  
Tyrosine Kinase ◽  
Serum Levels ◽  
Maternal Serum ◽  
Placental Growth Factor ◽  
Cochrane Library ◽  
Original Research ◽  
Multiple Gestation ◽  
Soluble Endoglin ◽  
Twin Pregnancies

Multiple gestation is one of the key risk factors for the occurrence of preeclampsia (PE). Soluble fms-like tyrosine kinase-1, placental growth factor, and soluble endoglin are molecules involved in the process of angiogenesis with a proven role in the pathogenesis of PE. The aim of the review was to summarize available data on maternal serum levels of the above-mentioned factors and their usefulness in predicting PE in twin pregnancies. Only original research articles written in English were considered eligible. Reviews, chapters, case studies, conference papers, experts’ opinions, editorials, and letters were excluded from the analysis. No publication date limitations were imposed. The systematic literature search using PubMed/MEDLINE, Scopus, Embase, and Cochrane Library databases identified 338 articles, 10 of which were included in the final qualitative analyses. The included studies showed significant differences in maternal serum levels of the discussed factors between women with twin pregnancies with PE and those who did not develop PE, and their promising performance in predicting PE, alone or in combination with other factors. The identification of the most effective algorithms, their prompt introduction to the clinical practice, and further assessment of the real-life performance should become a priority.

scholarly journals New Gestational Phase–Specific Cutoff Values for the Use of the Soluble fms-Like Tyrosine Kinase-1/Placental Growth Factor Ratio as a Diagnostic Test for Preeclampsia

Hypertension ◽  
2014 ◽  
Vol 63 (2) ◽  
pp. 346-352 ◽  
Author(s):  
Stefan Verlohren ◽  
Ignacio Herraiz ◽  
Olav Lapaire ◽  
Dietmar Schlembach ◽  
Harald Zeisler ◽  
...  
Keyword(s):  
Growth Factor ◽  
Tyrosine Kinase ◽  
Diagnostic Test ◽  
Placental Growth Factor ◽  
Cutoff Values ◽  
Factor Ratio

scholarly journals The role of angiogenic factors in preeclampsia

2014 ◽  
Vol 155 (47) ◽  
pp. 1860-1866 ◽  
Author(s):  
Bálint Alasztics ◽  
Nóra Gullai ◽  
Attila Molvarec ◽  
János Rigó Jr.
Keyword(s):  
Growth Factor ◽  
Tyrosine Kinase ◽  
Clinical Symptoms ◽  
Current Knowledge ◽  
Point Of Care ◽  
Serum Levels ◽  
Maternal Blood ◽  
Placental Growth Factor ◽  
Maternal Circulation ◽  
Early Onset Preeclampsia

Preeclampsia is one of the most common and most serious complications of pregnancy and the management of this condition still challenges obstetricians. Despite intensive research the etiology of preeclampsia still remains unclear. At the beginning of the 2000s preeclampsia-related research was directed towards factors that influence angiogenesis. Most studies have been carried out on the placental growth factor and soluble fms-like tyrosine kinase-1. Most publications confirm the increased concentrations of antiangiogenic factors and decreased concentrations of proangiogenic factors in maternal blood samples in preeclampsia even before the onset of clinical symptoms. According to our current knowledge antiangiogenic proteins are responsible for the endothelial dysfunction in the symptomatic stage of the disease. Placental growth factor and soluble fms-like tyrosine kinase-1 may have important roles in the prediction and treatment of the disease. The point of care detection of placental growth factor and soluble fms-like tyrosine kinase-1 may be used to predict preeclampsia. Rapid tests are available to determine the serum levels of the two proteins. Removal of soluble fms-like tyrosine kinase-1 from maternal circulation is a potential treatment option for early onset preeclampsia. Orv. Hetil., 2014, 155(47), 1860–1866.

scholarly journals Prediction of Preeclampsia-Related Adverse Outcomes With the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor)-Ratio in the Clinical Routine

Hypertension ◽  
2020 ◽  
Author(s):  
Lisa Antonia Dröge ◽  
Frank Holger Perschel ◽  
Natalia Stütz ◽  
Anna Gafron ◽  
Lisa Frank ◽  
...  
Keyword(s):  
Growth Factor ◽  
Tyrosine Kinase ◽  
Area Under The Curve ◽  
Placental Growth Factor ◽  
Adverse Outcomes ◽  
Low Risk ◽  
Cutoff Values ◽  
Elevated Liver Enzymes ◽  
Factor Ratio ◽  
Plgf Ratio

This retrospective real-world study investigated the clinical use of the sFlt-1 (soluble fms-like tyrosine kinase 1)/PlGF (placental growth factor) ratio alone or in combination with other clinical tests to predict an adverse maternal (maternal death, kidney failure, hemolysis elevated liver enzymes low platelets-syndrome, pulmonary edema, disseminated intravascular coagulation, cerebral hemorrhage, or eclampsia) or fetal (delivery before 34 weeks because of preeclampsia and/or intrauterine growth restriction, respiratory distress syndrome, necrotizing enterocolitis, intraventricular hemorrhage, placental abruption or intrauterine fetal death or neonatal death within 7 days post natum) pregnancy outcome in patients with signs and symptoms of preeclampsia. We evaluated the sFlt-1/PlGF-ratio cutoff values of 38 and 85 and evaluated its integration into a multimarker model. Of 1117 subjects, 322 (28.8%) developed an adverse fetal or maternal outcome. Patients with an adverse versus no adverse outcome had a median sFlt-1/PlGF-ratio of 177 (interquartile range, 54–362) versus 14 (4–64). Risk-stratification with the sFlt-1/PlGF cutoff values into high- (>85), intermediate- (38–85), and low-risk (<38) showed a significantly shorter time to delivery in high- and intermediate- versus low-risk patients (4 versus 8 versus 29 days). When integrating all available clinical information into a multimarker model, an area under the curve of 88.7% corresponding to a sensitivity, specificity, positive and negative predictive value of 80.0%, 87.3%, 75.0%, and 90.2% was reached. The sFlt-1/PlGF-ratio alone was inferior to the full model with an area under the curve of 85.7%. As expected, blood pressure and proteinuria were significantly less accurate with an area under the curve of 69.0%. Combining biomarker measurements with all available information in a multimarker modeling approach increased detection of adverse outcomes in women with suspected disease.

Sign in / Sign up

Export Citation Format

Share Document